Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction

Bayer

Status and phase

Completed

Phase 3

Conditions

Erectile Dysfunction

Treatments

Drug: Levitra (Vardenafil, BAY38-9456)

Study type

Interventional

Funder types

Industry

Identifiers

11182

Details and patient eligibility

About

To find out more information on how effective and safe vardenafil is at treating impotence in men living in Russia.

Enrollment

130 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males with ED according to the NIH definition (the inability to achieve or maintain penile erection sufficient for satisfactory sexual performance) for at least 3 months.
Heterosexual relationship
Age range: 18 years and older
Documented written Informed Consent
The subject must make at least four attempts at sexual intercourse (according to the question in the subject diary "Was sexual activity initiated with the intention of intercourse?") on four separate days during the untreated baseline period. At least 50% of attempts during this period must be unsuccessful, according to the following questions from the subject diary [at least one question should be answered "No"] "Were you able to achieve at least partial erection (some enlargement of the penis)?", "Were you able to insert your penis in your partner's vagina?" and "Did your erection last long enough for you to have successful intercourse?".

Exclusion criteria

Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
Presence of penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's disease) that in the opinion of the Investigator would significantly impair erectile function
Primary hypoactive sexual desire
Spinal cord injury
History of surgical prostatectomy (excluding TURP).
Retinitis pigmentosa
History of positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C.
History of positive test for HIV.9. Severe chronic or acute liver disease, history of moderate or severe hepatic impairment.
Clinically significant chronic hematological disease, which may lead to priapism such as sickle cell anemia and leukemia.
Bleeding disorder.
Significant active peptic ulceration.
Unstable angina pectoris
History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months
Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate > 100 bpm).
Resting hypotension (a resting systolic blood pressure of < 90 mm Hg) or hypertension (a resting systolic blood pressure > 170 mm Hg or a resting diastolic blood pressure > 110 mm Hg)
NYHA Class III and IV heart failure
Symptomatic postural hypotension within 6 months of visit 1.
History of malignancy within the past 5 years (other than squamous or basal cell skin cancer).

Concomitant Medication:

Subjects who are taking nitrates or nitric oxide donors.
Subjects who are taking anti-androgens
Subjects who are taking androgens.
Subjects who take anticoagulants, except for antiplatelet agents.
Subjects who have received any investigational drug (including placebo) within 30 days of visit 1.6. Use of any treatment for ED within the 7 days of visit 1 or during the study, including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
Subjects who are taking the following potent inhibitors of cytochrome P- 450 3A4: HIV protease inhibitors such as ritonavir or indinavir, the anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed) or erythromycin.
Subjects who are taking alpha-blockers.

Abnormal Laboratory Values:

Subjects who have a serum total testosterone level greater than 25% below the lower limit of normal according to the range of the testing laboratory
Subjects with a serum creatinine >3.0 mg/dl
Elevation of AST and/or ALT >3X the ULN.
Diabetic subjects with an HbA1c >12%.